P

Prothena Corp
D

PRTA

10.880
USD
-0.46
(-4.06%)
مغلق
حجم التداول
15,004
الربح لكل سهم
-3
العائد الربحي
-
P/E
-5
حجم السوق
585,637,564
أصول ذات صلة
ALNY
ALNY
-21.680
(-8.26%)
240.730 USD
AMGN
AMGN
-13.59
(-4.38%)
294.28 USD
B
BLUE
0.06000
(1.23%)
4.94000 USD
C
CRSP
0.000
(0.00%)
32.650 USD
E
EDIT
-0.08500
(-7.59%)
1.03500 USD
GILD
GILD
-5.120
(-4.56%)
107.260 USD
ILMN
ILMN
-2.720
(-3.56%)
73.650 USD
N
NTLA
-0.30500
(-4.43%)
6.58000 USD
REGN
REGN
-32.25
(-5.28%)
578.63 USD
S
SGMO
0.03780
(6.10%)
0.65790 USD
المزيد
الأخبار المقالات

العنوان: Prothena Corp

القطاع: Healthcare
الصناعة: Biotechnology
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.